IRX Therapeutics, Inc. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

IRX Therapeutics, Inc. ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "IRX Therapeutics, Inc. - Product Pipeline Review - 2012" provides data on the IRX
Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete
with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, IRX Therapeutics, Inc.'s
corporate website, SEC filings, investor presentations and featured press releases, both from IRX Therapeutics, Inc. and
industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- IRX Therapeutics, Inc. - Brief IRX Therapeutics, Inc. overview including business description, key information and facts, and its
locations and subsidiaries.
- Review of current pipeline of IRX Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of IRX Therapeutics, Inc. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IRX Therapeutics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate IRX Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IRX Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IRX Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives
to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IRX Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IRX Therapeutics, Inc. and identify potential opportunities in those areas.

IRX Therapeutics, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
IRX Therapeutics, Inc. Snapshot 5
IRX Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
IRX Therapeutics, Inc. ' Research and Development Overview 6
Key Therapeutic Areas 6
IRX Therapeutics, Inc. ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
Pipeline Products ' Combination Treatment Modalities 10
IRX Therapeutics, Inc. ' Pipeline Products Glance 11
IRX Therapeutics, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
IRX Therapeutics, Inc. ' Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
IRX Therapeutics, Inc. ' Drug Profiles 13
IRX-2 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
IRX-2 + DepoVax Cancer Vaccine 15
R&D Progress 15
IRX-3 16
R&D Progress 16
IRX-4-6 17
R&D Progress 17
methyl inosine monophosphate 18
R&D Progress 18
IRX Therapeutics, Inc. ' Pipeline Analysis 19
IRX Therapeutics, Inc. ' Pipeline Products by Therapeutic Class 19
IRX Therapeutics, Inc. ' Pipeline Products by Route of Administration 20



IRX Therapeutics, Inc. ' Pipeline Products By Mechanism of Action 21
IRX Therapeutics, Inc. ' Recent Pipeline Updates 22
IRX Therapeutics, Inc. ' Locations And Subsidiaries 23
Head Office 23
Financial Deals Landscape 24
IRX Therapeutics, Inc., Deals Summary 24
IRX Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 25
Venture Financing 25
IRX Therapeutics Raises $1.5 Million In Venture Financing 25
IRX Therapeutics Raises $8 Million In Venture Financing 26
IRX Therapeutics Secures $2 Million In Venture Financing 27
IRX Therapeutics Secures $25 Million In Series A Financing 28
Partnerships 29
IRX Therapeutics Enters Into Research Collaboration With Pharma Company 29
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 30
IRX Therapeutics Enters Into Collaboration Agreement With NCRC 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables

IRX Therapeutics, Inc., Key Information 5
IRX Therapeutics, Inc., Key Facts 5
IRX Therapeutics, Inc. ' Pipeline by Indication, 2012 7
IRX Therapeutics, Inc. ' Pipeline by Stage of Development, 2012 8
IRX Therapeutics, Inc. ' Monotherapy Products in Pipeline, 2012 9
IRX Therapeutics, Inc. ' Combination Treatment Modalities in Pipeline, 2012 10
IRX Therapeutics, Inc. ' Phase II, 2012 11
IRX Therapeutics, Inc. ' Pre-Clinical, 2012 12
IRX Therapeutics, Inc. ' Pipeline By Therapeutic Class, 2012 19
IRX Therapeutics, Inc. ' Pipeline By Route of Administration, 2012 20
IRX Therapeutics, Inc. ' Pipeline Products By Mechanism of Action, 2012 21
IRX Therapeutics, Inc. ' Recent Pipeline Updates, 2012 22
IRX Therapeutics, Inc., Deals Summary 24
IRX Therapeutics Raises $1.5 Million In Venture Financing 25
IRX Therapeutics Raises $8 Million In Venture Financing 26
IRX Therapeutics Secures $2 Million In Venture Financing 27
IRX Therapeutics Secures $25 Million In Series A Financing 28
IRX Therapeutics Enters Into Research Collaboration With Pharma Company 29
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 30



IRX Therapeutics Enters Into Collaboration Agreement With NCRC 31

List of Figures

IRX Therapeutics, Inc. ' Pipeline by Indication, 2012 7
IRX Therapeutics, Inc. ' Pipeline by Stage of Development, 2012 8
IRX Therapeutics, Inc. ' Monotherapy Products in Pipeline, 2012 9
IRX Therapeutics, Inc. ' Combination Treatment Modalities in Pipeline, 2012 10
IRX Therapeutics, Inc. ' Pipeline By Therapeutic Class, 2012 19
IRX Therapeutics, Inc. ' Pipeline By Route of Administration, 2012 20


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


IRX Therapeutics, Inc. ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

IRX Therapeutics, Inc. ' Product Pipeline Review ' 2012